Table 3.
Multivariate Analyses Of Risk Factors For The Isolation Of CP-CRE Group Versus Non-CP-CRE Group, CP-CRE Group Versus ESBL Group, And Non-CP-CRE Group Versus ESBL Group
| Variable | 95% CI | OR | P Value |
|---|---|---|---|
| CP-CRE vs non-CP-CRE | |||
| Age | NA | NA | 0.04 |
| Admission to ICU | 0.59–7.55 | 2.12 | 0.25 |
| Length of ICU stay | NA | NA | 0.03 |
| Cancer | 1.22–15.46 | 4.35 | 0.023 |
| Liver cancer | 0.28–30.16 | 2.91 | 0.37 |
| Use of drainage tube | 0.62–10.34 | 2.23 | 0.19 |
| Previous carbapenem exposure | 1.91–30.77 | 7.67 | 0.004 |
| CP-CRE vs ESBLs | |||
| Age | NA | NA | 0.01 |
| Admission to ICU | 0.10–2.20 | 0.46 | 0.33 |
| Length of ICU stay | NA | NA | 0.02 |
| Transfusion | 3.15–93.72 | 17.19 | 0.001 |
| Cancer | 3.56–71.37 | 15.91 | <0.001 |
| Chemotherapy | 0.17–5.16 | 0.94 | 0.94 |
| Venous catheterization | 1.82–35.90 | 8.10 | 0.006 |
| Previous carbapenem exposure | 5.03–154.19 | 27.86 | 0.001 |
| Non-CP-CRE vs ESBLs | |||
| Length of ICU stay | NA | NA | 0.018 |
| Transfusion | 0.32–4.78 | 1.24 | 0.75 |
| Venous catheterization | 3.03–34.87 | 10.29 | 0.001 |
Abbreviation: NA, Not applicable.